150 results about "Lung tissue" patented technology

The invention provides a pulmonary nodule display method and device, electronic equipment and a storage medium, and the method comprises the steps: segmenting a three-dimensional reconstruction image of the chest of a target patient to obtain a preoperative segmentation image, the three-dimensional reconstruction image being obtained based on preoperative CT data, and the preoperative segmentation image comprising the position information of a pulmonary nodule; segmenting the video image of the intraoperative lung tissue of the target patient collected by the thoracoscope in real time to obtain an intraoperative segmented image; feature matching is conducted on the preoperative segmented image and the intra-operative segmented image, the lens pose of the thoracoscope is determined, the preoperative segmented image is mapped into a two-dimensional reference image based on the lens pose, and the two-dimensional reference image comprises the position information of the pulmonary nodule; and carrying out image registration on the two-dimensional reference image and the intra-operative segmented image, and carrying out pulmonary nodule marking on the intra-operative segmented image to obtain a video image for displaying pulmonary nodules in real time. The position of the pulmonary nodule in the operation is accurately displayed in real time in a non-invasive mode, and the operation efficiency is improved.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

The invention relates to application of roxburgh rose-derived exosomes (RrNVs) in preparation of products for preventing, improving or treating acute lung injury (ALI). Specifically, the rosa roxburghii tratt exosome (RrNVs) can effectively inhibit inflammation, improve the acute lung injury symptom, reduce the release of inflammatory cells and inflammatory mediators in the acute lung injury state, and relieve the pulmonary edema condition, the lung tissue leakage condition and the lung capillary permeability condition in the inflammatory state. Meanwhile, the RrNVs can also regulate and control the intestinal flora structure, improve the abundance of beneficial bacteria and reduce the abundance of harmful bacteria, and the discovery provides a basis for the RrNVs as potential functional food, medicine and the like of ALI.

The invention relates to application of bifidobacterium animalis in preparation of a product for preventing, treating or adjunctively treating pneumonia, and belongs to the technical field of microorganisms. The invention aims to solve the technical problem that the existing treatment of acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is mainly based on supportive means and lacks special-effect treatment drugs. According to the key point of the technical scheme, a new strain, namely the Bifidobacterium animalis ORG01 is provided, the preservation number is GDMCC NO: 67122, and the strain has good technical effects in the aspects of improving the acute lung injury effect, the strain stability, the product application convenience and the like. According to an experimental test, the bifidobacterium animalis ORG01 disclosed by the invention can be used for remarkably recovering the lung organ index of an LPS-induced acute lung injury model mouse, the TNF-alpha content in serum and the mRNA expression level of IL-6 in lung tissues to normal levels.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

The invention relates to the technical field of novel biological nanomaterials, in particular to a lung-targeted exosome complex as well as a preparation method and application thereof. The lung targeting type exosome complex is prepared from an NK cell exosome, lipid nanoparticles and an entrapped anti-tumor nucleic acid drug, the NK cell exosome is obtained by extracting a natural killer cell NK-92MI of a human malignant non-Hodgkin lymphoma patient through a differential centrifugation method. The anti-tumor nucleic acid drug is a specific nucleic acid drug targeting a key canceration driving gene in non-small cell lung cancer. The lung targeting type exosome complex prepared by the invention is an excellent and stable drug delivery carrier, has a good lung tissue targeting function, enhances the tumor targeting effect of the exosome, also exerts the tumor cell killing function of the exosome, and has important significance for the treatment of non-small cell lung cancer.

The invention discloses a high-frequency full-chest oscillation sputum excretion method and system based on clinical data self-adaptive regulation and control, and the method comprises the steps: building an individualized propagation model of thorax and lung tissues through collecting individualized clinical data of a patient and chest multipoint acoustic and mechanical short-range response; the current body position of a patient is input into the model, a chest drainage path is obtained, oscillation control parameters are generated under the constraint of the path, and the oscillation control parameters are used for driving equipment to synthesize pressure traveling waves which are directionally propagated in multiple areas of the chest wall. In the execution process, safety gating control is conducted in combination with electrocardio and breathing phases, meanwhile, aerosol echoes and high-frequency impedance disturbance are collected to serve as feedback signals, and feedback data are formed after the feedback signals are aligned with an execution time sequence and used for dynamically updating the individualized propagation model and oscillation control parameters. According to the invention, accurate regulation and control can be carried out according to individual differences and real-time physiological statuses of different patients, the sputum drainage effect is effectively enhanced, the safety and comfort of treatment are improved, and the clinical application value is high.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

The invention relates to the technical field of radiotherapy, and discloses a multi-modal image fusion guided chest tumor adaptive radiotherapy system. The system comprises an asynchronous bimodal sensing module, a spectrum preprocessing module, a parameter inversion module, a boundary construction module and a biomechanical calculation module. According to the method, the feedback voxel-level velocity field is utilized to execute Lagrange reverse warping on the high-energy projection with physical time delay, and motion artifacts are eliminated; and dynamically updating the Young modulus of the lung tissue mechanical model based on the inverted real-time electron density, and solving a full-field three-dimensional displacement field in combination with double boundary conditions of body surface flexibility and internal skeleton rigidity so as to reconstruct a tumor target region and generate a beam control instruction. According to the method, through closed-loop interaction of image physics and biomechanics, the problems of dual-energy imaging motion artifact interference and insufficient lung tissue fixed parameter modeling precision are solved, and accurate self-adaptive tracking of a tumor target region is realized.

The application discloses an FPR1 polypeptide blocker against lung inflammation and application thereof. The application provides a polypeptide shown in Sequence NO. 1, which can significantly improve lung tissue structure damage of a lung inflammation model mouse, reduce a proinflammatory factor level, reduce neutrophil infiltration, and show obvious anti-lung inflammation efficacy. Therefore, the polypeptide shown in Sequence NO. 1 has a prospect of development into an anti-lung inflammation drug.

The invention relates to the technical field of hydrops quantitative evaluation, and discloses an ultrasound-based pleural hydrops quantitative evaluation system, which comprises an image acquisition module, a boundary division module, a trajectory analysis module, a feature judgment module, a mode classification module and a quantitative evaluation determination module, the positioning module is used for positioning an area which deforms along with breathing movement in the ultrasonic image sequence, and dividing a suspected effusion cavity boundary based on the consistency of a deformation mode; the trajectory analysis module is used for analyzing moving trajectories of the suspected effusion cavity boundary at different breathing phases and extracting regularity features and amplitude change features of the moving trajectories; the feature judgment module is used for judging the mechanical coupling state of the suspected effusion cavity and the surrounding lung tissue according to the combination of the regularity feature and the amplitude change feature; according to the method, the comprehensiveness and accuracy of quantitative evaluation of the pleural effusion are remarkably improved, and a more valuable decision basis is provided for clinical diagnosis and treatment.

The application discloses a kind of hardness correlation liver cancer lung premetastatic niche mouse model construction method, it includes the following steps: (1) in vitro enrichment respectively on the low hardness substrate of hardness 6kPa and the high hardness substrate of hardness 16kPa, the condition culture supernatant of mouse liver cancer cell Hepa1-6 that is cultured and grows, respectively named mL-CM and mH-CM;(2) mL-CM and mH-CM are respectively injected into two groups of mice using tail vein injection mode, every 1 day injection 1 time, until the 26th day, during continuous monitoring the recruitment of BMDCs in fresh lung tissue, while with the induction endpoint, i.e. 26th day premetastatic niche mark feature detection includes lung tissue matrix remodeling, immunosuppression, angiogenesis, vascular permeability and inflammation etc..The method has the advantages of short modeling cycle, easy operation, controllable induction condition, can comprehensively and accurately evaluate the common characteristics of liver cancer lung premetastatic niche formation etc..

Novel kisspeptin-13 or KP-13 peptides and KP-13 satellites or modified peptides (KPSATs) are disclosed having improved therapeutic benefits in regulating pathophysiological changes in various tissues, particularly lung tissue. These KPSATs have improved antiproliferative effects and non-cytotoxic effects on airway smooth muscle cells and tissue.

The invention discloses an application of thermal sensitive Sibestein granules in treating / or preventing asthma, and belongs to the technical field of biological medicines. The invention finds that the thermal sensitive Sibestein granules can reduce the total number of cells and the number of eosinophilic granulocytes, neutrophil granulocytes and lymphocytes in asthma mice BALF, reduce the level of cell factors in asthma mice BALF and IgE in serum, reduce exudation of inflammatory substances in airway and alveolar tissues of asthma mice and infiltration of inflammatory cells, improve the lesion degree of lung tissues, and improve the curative effect of the lung tissues. The action mechanism may be related to regulation and control of MAPK / NF-kappa B signal channel related protein expression, so that inflammatory response and cell apoptosis are inhibited, and airway inflammation of mice is relieved.

The utility model discloses a pulmonary nodule positioning needle releasing device in the technical field of pulmonary nodule positioning needles, which comprises an outer tube, a handle is mounted at one end of the outer tube, an inner tube penetrates through the inner side of the handle, a connecting rod penetrates through the inner tube, and a positioning piece is placed at one end of the connecting rod and located on the inner side of the inner tube. A limiting piece is installed on the inner side, close to one end, of the inner tube, the outer tube is driven by the handle to be inserted into the body of a patient, then the inner tube is inserted into the inner side of the outer tube to slide, the positioning piece at one end of the inner side of the inner tube is pushed by the connecting rod to be placed in lung tissue, and the positioning piece is limited and fixed by the limiting piece. The inner tube is limited and fixed through the fixing piece, the inner tube is prevented from shaking or shifting, and the problems that the stability of supporting of the positioning needle is low, the positioning needle is prone to shifting or shaking due to lung tissue during release, the limiting effect of the inner tube structure on the inner side of the puncture tube is poor, and convenience and practicability of release and position adjustment of the positioning needle are affected are solved.

The innovative aspirator head comprises a tubular handle and a working head part arranged at the front end of the tubular handle, an aspiration channel is formed in the tubular handle, the working head part is an integrally formed flat wedge-shaped aspiration head, and the aspiration channel is communicated with the aspiration channel. At least one suction hole communicated with the suction channel is formed in the stripping working surface; in the whole stripping process, wound surface errhysis is continuously sucked away through the suction holes, it is ensured that the operation view is clear, and the flat wedge-shaped head cannot pierce lung tissue due to the large contact area and the small pressure intensity; meanwhile, the flat wedge-shaped head is easy to insert into a gap, the pure flat blunt end ensures that the front end cannot be punctured, the clinical pain point that a traditional round-head aspirator is easy to poke into or tear fragile lung tissue is effectively solved, stable poking and separation of a fiberboard are achieved by increasing the stress area, and the safety and controllability of an operation are remarkably improved.

The application provides an application of Buyang Huanwu Decoction in the preparation of a product for treating high altitude pulmonary injury of qi deficiency and blood stasis syndrome, and belongs to the technical field of medicines. After the prescription of the Buyang Huanwu Decoction is decocted with water, the decoction is used for treating high altitude pulmonary injury, can reduce pathological injury of lung tissues, reduce thickening of alveolar walls, make lung tissue structure clearer, and close to normal lung tissue morphology; meanwhile, the decoction can enhance exercise capacity, reduce asthenia symptoms of high altitude pulmonary injury of qi deficiency and blood stasis syndrome, and effectively treat high altitude pulmonary injury of qi deficiency and blood stasis syndrome.

The invention belongs to the technical field of biological medicine, and relates to application of miRNA targeted regulation in treatment of acute respiratory distress syndrome, in particular to application of a miR-144 inhibitor in preparation of a medicine for improving glucocorticoid treatment sensitivity of an ARDS patient. Research on a lipopolysaccharide-induced ARDS rat model finds that miR-144 participates in regulation and control of glucocorticoid receptor beta (GR beta) and NF-kappa B signal pathways in the ARDS inflammatory reaction process, the number of neutrophils in alveolar lavage fluid and the level of inflammatory factors such as IL-6 and TNF-alpha can be remarkably reduced by using the miR-144 inhibitor and glucocorticoid for treatment, and the application of the miR-144 inhibitor to treatment of the pulmonary alveolar lavage fluid in the treatment of the pulmonary alveolar lavage fluid is broad. The wet-to-dry ratio and pathological injury score of lung tissues are reduced, and GR beta and NF-kappa B expression is inhibited, so that the anti-inflammatory effect of glucocorticoid is remarkably enhanced. The invention provides a treatment strategy for improving glucocorticoid resistance of ARDS patients by taking miR-144 as a target for the first time, and provides a new drug target and a technical scheme for accurate treatment of ARDS.

The application belongs to the technical field of biological medicine, and particularly relates to the use of a lung extracellular matrix hydrogel in the preparation of a lung injury repair material. The application grafts methacrylic anhydride groups on a lung tissue-derived extracellular matrix, and provides a lung extracellular matrix hydrogel which can be rapidly photo-crosslinked, has high stability, effectively promotes angiogenesis, and prevents postoperative leakage. The photo-crosslinked lung extracellular matrix hydrogel of the application is applied to a lung injury animal model, significantly promotes angiogenesis, promotes alveolar regeneration, and also significantly reduces the fibrosis level. Compared with a sealing agent alpha-cyanopropyl acrylate gel and a fibrin glue which are used in clinical application, the photo-crosslinked lung extracellular matrix hydrogel has excellent effects on repairing lung injury, provides a new strategy for repairing traumatic and iatrogenic lung injury, and has a good application prospect.

The invention discloses a pulmonary nodule real-time positioning method and a pulmonary nodule real-time positioning device based on artificial intelligence multi-modal image fusion technology applied to a sub-pulmonary lobe resection operation, which are applied to the technical field of data processing, a three-dimensional collapsed lung model is generated by acquiring a lung medical image and a three-dimensional model in combination with operation parameters, and features of the three-dimensional collapsed lung model are automatically identified. Endoscope dynamic images are collected in real time in an operation, and the three-dimensional collapse lung model is finely adjusted after image features are extracted, so that the three-dimensional collapse lung model is accurately matched with an actual lung tissue form in the operation. By means of the artificial intelligence multi-mode image fusion technology, the endoscope image and the three-dimensional model are deeply fused, and the lung three-dimensional structure and the accurate pulmonary nodule position under the endoscope view field are presented in real time. By integrating artificial intelligence, computer vision, a collapse algorithm and a multi-modal image fusion technology, a doctor is assisted to clearly identify lung tissue and nodule positions in an operation, the accuracy of the operation is effectively improved, the operation time is shortened, and the operation is safely completed with high quality.

The invention discloses an iRGD-modified mesenchymal stem cell outer vesicle-loaded WZ35 dual-targeting drug delivery composition, which is characterized in that rat bone marrow mesenchymal stem cell-derived extracellular vesicles are used as carriers, curcumin analogues WZ35 are loaded in the carriers, and iRGD peptides are covalently modified on the surfaces of the carriers, so that passive targeting and active targeting synergistic delivery is realized; efficient entrapment of the medicine is achieved in an extrusion or co-incubation mode, the particle size of the obtained composition is 100-200 nm, and the dispersity is good; in-vivo experiments show that compared with free WZ35, the composition has the advantages that the enrichment efficiency of WZ35 in lung tissue is remarkably improved, right ventricular systolic pressure can be effectively reduced in an anoxia-induced pulmonary arterial hypertension rat model, pulmonary vascular remodeling is improved, and the invention provides a novel efficient and safe drug delivery strategy for targeted therapy of lung diseases.

The utility model discloses a lymph node developing tracer agent locating hook, relates to minimally invasive surgery auxiliary instrument technical field, including holding cylinder, puncture needle, anchor needle claw, the puncture needle is fixed in the centre of holding cylinder tail end, the push tube is inserted in the puncture needle, the push tube tail end is fixed with the connector, anchor needle claw is fixed in the anchor needle claw, the anchor needle claw is fixed in the anchor needle claw, and the anchor needle claw is fixed in the anchor needle claw. A clamping-in head is fixedly arranged on the side face of the holding cylinder, and a safety structure for preventing the anchoring needle claw from being accidentally released is arranged at the position, at the clamping-in head, of the holding cylinder. The positioning hook is composed of the four groups of anchoring needle claws, the four groups of anchoring needle claws are in four-claw arc shapes and are made of nickel-titanium memory alloy materials, when the positioning claws are released, lung tissue is not prone to being torn, the safety structure is arranged, and the safety structure can prevent the positioning claws from being accidentally released when puncture of the puncture needle is not finished. Scales are arranged on the outer walls of the puncture needle and the positioning line, so that a doctor is assisted in determining the puncture depth and the release depth under the condition that an external CT instrument is not used.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of invertible pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape. In these embodiments, a portion of the device is invertible. Thus, each device is able to store energy at least in the inversion, wherein the energy is utilized to continually tension the lung as the device relaxes toward its original shape.

The application discloses application of a PRMT3 inhibitor SGC707 in preparation of a drug for treating pulmonary fibrosis, and for the first time verifies that a selective PRMT3 inhibitor SGC707 can dose-dependently inhibit expression of fibrosis markers such as COL1A1 and alpha-SMA in fibroblasts induced by TGF-beta 1 in vitro; in a bleomycin (BLM) induced mouse pulmonary fibrosis model, SGC707 administration can significantly improve lung tissue collagen deposition, reduce inflammatory cell infiltration, repair alveolar structure damage, and effectively down-regulate expression levels of fibrosis related proteins in lung tissues. It is proved that PRMT3 is a functional target with important intervention value in pulmonary fibrosis, SGC707 has definite anti-pulmonary fibrosis activity in vitro and in vivo, and a new drug strategy is provided for treatment of pulmonary fibrosis.

The present application belongs to the technical field of livestock and poultry anti-virus micro-ecological preparation, and particularly relates to a bacillus compound preparation containing grape seed extract and application of the bacillus compound preparation in preparation of a medicine for treating or preventing PRRSV infection. Two strains of bacillus with significant inhibition of PRRSV infection and synergistic effect after being combined with grape seed extract are screened, and the preservation numbers are CCTCC NO: M2026187 and CCTCC NO: M2026186 respectively. The test results show that the compound preparation can significantly reduce the infection activity and proliferation capacity of PRRSV in cells and pigs, effectively reduce the clinical symptoms of pigs caused by PRRSV infection, and relieve the damage degree of lung tissue organs of pigs. The potential synergistic effect between the bacillus compound bacteria and grape seed proanthocyanidin provides a new technical scheme for effective prevention and control of porcine reproductive and respiratory syndrome.

The application belongs to the technical field of biological medicine, and more particularly relates to nanoparticles TK-PSBs / CBD@Met, a preparation method therefor and application thereof. The nanoparticles TK-PSBs / CBD@Met are nanoparticles formed by wrapping cannabidiol and metformin with thione-modified lung surfactant biomimetic liposomes. In vitro experiments have confirmed that the nanoparticles TK-PSBs / CBD@Met can effectively inhibit the fibrosis process of BEAS-2B cells induced by silicon dioxide. Animal experiments have shown that the nanoparticles TK-PSBs / CBD@Met can significantly improve the damage to the lung tissue structure and abnormal deposition of collagen caused by SiO2 exposure, and alleviate the pathological progression of silicosis fibrosis.

The invention discloses application of inhibiting combination of Hic-5 and SMAD7 and / or inhibiting Hic-5 in treatment of pulmonary arterial hypertension, and finds that PLEKHH2 and SMAD7 have competitive combination with Hic-5 protein in lung tissue, more SMAD7 can be released into cytoplasm by preventing combination of Hic-5 and SMAD7, and SMAD2 / 3 phosphorylation is inhibited for the first time, so that the purpose of treating the pulmonary arterial hypertension is achieved. The invention provides a new research and development direction for the development of pulmonary arterial hypertension treatment medicines.

The invention belongs to the technical field of biological analysis, and relates to a method for performing mass spectrum imaging analysis on lung tissues and application. In order to solve the problem that the structural integrity is difficult to maintain in the lung tissue freezing and slicing process, a liquid shaping agent is adopted to conduct internal perfusion on fresh lung tissue, the airway and the pulmonary alveoli are filled, and the shaping agent supports the lung tissue to maintain the natural state in the subsequent operation after being solidified at low temperature. The prepared lung tissue frozen section can be used for mass spectrum imaging analysis and research.

The application belongs to the technical field of biological medicine, and particularly relates to application of calcium chelator BAPTA and a pharmaceutical composition. The calcium chelator BAPTA delays aging of lung fibroblasts and lung tissues by eliminating calcium accumulation in lung fibroblasts, reducing accumulation of reactive oxygen species ROS (ROS) in lung fibroblasts, DNA damage, and release of inflammatory factors. The calcium chelator BAPTA ultimately realizes the function of treating pulmonary fibrosis by inhibiting weight loss, lung tissue inflammatory cell infiltration, lung collagen deposition, and expression of fibrosis markers. The application provides a new drug source for delaying aging of lung fibroblasts and lung tissues and studying occurrence and development of pulmonary fibrosis. The drug is safe and reliable, has strong pharmacological action, small side effects, and definite curative effect.